heterologous liver-derived stem cells (Fresenius Medical Care)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameheterologous liver-derived stem cells (Fresenius Medical Care)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionCarbamoyl phosphate synthetase 1 stimulantsOrnithine carbamoyltransferase stimulants
TargetsCarbamoyl phosphate synthetase 1Ornithine carbamoyltransferase
Therapy Area/IndicationsOrnithine Carbamoyltransferase Deficiency DiseaseCarbamoyl-Phosphate Synthase I Deficiency DiseaseLiver Failure, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFresenius Medical Care
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFresenius Medical Care
Active IndicationsN/A
Inactive IndicationsOrnithine Carbamoyltransferase Deficiency DiseaseCarbamoyl-Phosphate Synthase I Deficiency DiseaseLiver Failure, Acute

Other Information

ATC CodeN/A
Related LinksN/A